Talphera (TLPH) Cash & Equivalents (2010 - 2026)
Talphera (TLPH) posted Cash & Equivalents of $17.1 million for Q2 2026, down 19.1% on a QoQ basis from $21.1 million in Q1 2026, and up 151.45% year-over-year from $6.8 million in Q2 2025.
Analysis
Talphera (TLPH) Cash & Equivalents (2010 - 2026) Analysis & Trends
Talphera has reported Cash & Equivalents for 17 years, with the latest figure at $17.1 million in Q2 2026.
- On a quarterly basis, Cash & Equivalents rose 151.45% year-over-year to $17.1 million in Q2 2026; TTM through Jun 2026 was $17.1 million, a 151.45% increase from a year earlier, with the FY2025 full-year figure at $20.4 million, up 129.96% from the prior year.
- Cash & Equivalents was $17.1 million for Q2 2026 at Talphera, down from $21.1 million in the prior quarter.
- The five-year high for Cash & Equivalents was $39.3 million in Q1 2022, with the low at $5.4 million in Q1 2025.
- Average Cash & Equivalents over 5 years is $16.5 million, with a median of $15.5 million recorded in 2024.
- The sharpest annual moves came in 2023 and 2026: Cash & Equivalents tumbled 73.46% in 2023, then surged 291.76% in 2026.
- Over 5 years, Cash & Equivalents stood at $20.8 million in 2022, then tumbled by 54.83% to $9.4 million in 2023, then declined by 5.52% to $8.9 million in 2024, then surged by 129.96% to $20.4 million in 2025, then retreated by 16.22% to $17.1 million in 2026.
- The last three Cash & Equivalents figures came in at $17.1 million (Q2 2026), $21.1 million (Q1 2026), and $20.4 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 13.99 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 3.18 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 6.14 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 2.46 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 3.58 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 1.72 Bn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 1.71 Bn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 1.29 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 1.25 Bn |
| 10 | Talphera | 92.90 Mn | 92.90 Mn | - | 17.08 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 17.08 Mn |
| Mar 31, 2026 | 21.11 Mn |
| Dec 31, 2025 | 20.38 Mn |
| Sep 30, 2025 | 21.29 Mn |
| Jun 30, 2025 | 6.79 Mn |
| Mar 31, 2025 | 5.39 Mn |
| Dec 31, 2024 | 8.86 Mn |
| Sep 30, 2024 | 11.12 Mn |
| Jun 30, 2024 | 14.02 Mn |
| Mar 31, 2024 | 18.58 Mn |
| Dec 31, 2023 | 9.38 Mn |
| Sep 30, 2023 | 13.39 Mn |
| Jun 30, 2023 | 7.41 Mn |
| Mar 31, 2023 | 13.35 Mn |
| Dec 31, 2022 | 20.77 Mn |
| Sep 30, 2022 | 20.93 Mn |
| Jun 30, 2022 | 27.92 Mn |
| Mar 31, 2022 | 39.35 Mn |
| Dec 31, 2021 | 51.63 Mn |
| Sep 30, 2021 | 8.27 Mn |